LABT
Lakewood-Amedex Biotherapeutics Inc. Common StockNASDAQ
Healthcare • Biotechnology
Updated 1 day ago
Coverage building
$0.69-5.08%
Close Oct 13, 2026
- Market cap
- $985.2K
- 1 month
- -67.3%
- 3 months
- -71.4%
- 1 year
- —
- Dividend
- No dividends on record
- Short interest
- 130.7K sharessettled Sep 30, 2026 · FINRA
End-of-day close from stored market data, not a live quote.
Portfolio context
Sign in to see your position size
We’ll show you if LABT is in your portfolio and how much it contributes.
Sign inMarket context
Loading market dates
No upcoming ex-dividend date announced
No 8-K filings in the last 30 days.
Smart money context
Institutional coverage is still building for this ticker.
Unlock crowding heatmapUnlock filer discoveryInsider context
Sentiment: unknown
No recent insider trades detected.
Red flags: 0
Largest 13-F holders · Q2 2026
6 filers reported a long position in LABT for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
Q1 2026 shares are adjusted for the 2026-06-22 1-for-10 reverse split.
| Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|
| Marex Group Ltd | $151.2K | 48.2K | New |
| HRT FINANCIAL LP | $140K | 44.8K | New |
| UBS Group AG | $12.9K | 4.1K | New |
| Tower Research Capital LLC (TRC) | $2K | 624 | New |
| OSAIC HOLDINGS, INC. | $433 | 138 | New |
| Blue Trust, Inc. | $35 | 11 | New |
Get the Full Analysis for LABT
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.